A study by an international research collaborative reports a stunning blood modification method that not only protects red blood cells for perfusion-based transplant organ cryostorage, but could make blood types cross-compatible and eventually enable blood transfusions between species.
Silicon exoskeletons for blood cells: Engineered blood cells successfully transfused between species retrieved 30 August 2024 from https://medicalxpress.com/news/2024-08-silicon-exoskeletons-blood-cells-successfully.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Engineered NK cells with IL-21 show strong antitumor activity against glioblastomaNatural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.
Read more »
Engineered exosome-based drug delivery system shows promise for ovarian cancer therapyOvarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer metastases, leading to a low survival rate for ovarian cancer patients.
Read more »
FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Read more »
FDA approves engineered cell therapy for treating rare sarcomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Read more »
Engineered heart tissues uncover new mechanisms in lupus-related heart damageCardiovascular disease is the leading cause of death in patients suffering from lupus, an autoimmune disease in which our immune system attacks our own tissues and organs, the heart, blood, lung, joints, brain, and skin.
Read more »
Engineered human cardiac tissue reveals how lupus autoantibodies damage the heartStudy demonstrates that autoantibodies in systemic lupus erythematosus (SLE) patients contribute to myocardial injury by binding to and impairing stressed cardiac cells, offering insights into potential therapeutic targets.
Read more »